Share This Author
A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.
- D. Mrazek, J. Hornberger, C. Altar, Irina Degtiar
- Medicine, PsychologyPsychiatric Services
- 1 August 2014
Treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion, and underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment- resistant depression.
Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection
Brain-derived neurotrophic factor has a substantial capacity to rescue axotomized cholinergic neurons when delivered effectively, according to the patterns of distribution of radiolabeled BDNF and NGF injected into the lateral ventricle.
Neurotrophin trafficking by anterograde transport
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
- J. Kennedy, C. Altar, Danielle L. Taylor, Irina Degtiar, J. Hornberger
- Medicine, PsychologyInternational Clinical Psychopharmacology
- 1 March 2014
The societal and economic burden of treatment-resistant schizophrenia (TRS) remains common and costly, despite availability of many treatment options, and contributes to a significant loss in patient quality of life.
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function.
Time Course of Adaptations in Dopamine Biosynthesis, Metabolism, and Release Following Nigrostriatal Lesions: Implications for Behavioral Recovery from Brain Injury
Molecular increases in dopamine metabolism, release, and biosynthesis occur rapidly within neostriatal terminals that survive a lesion, suggesting that mobilization of dopaminergic function could contribute to the recovery from the behavioral deficits of partial denervation by increasing the availability of dopamine to neostRIatal dopamine receptors.
Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy
- C. Altar, J. Hornberger, A. Shewade, Victor Cruz, Jill Garrison, D. Mrazek
- Psychology, MedicineInternational Review of Psychiatry
- 1 October 2013
The preponderance of evidence supports the validity of analyzing nucleotide polymorphisms in CYP and pharmacodynamic genes to predict the metabolism, safety, or therapeutic efficacy of psychotropic medications commonly used for the treatment of depression, schizophrenia, and bipolar illness.
Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain
- L. Mamounas, Medium Blue, J. Siuciak, C. Altar
- Biology, PsychologyJournal of Neuroscience
- 1 December 1995
Investigation of chronic pain parenchymal administration of the neurotrophins brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) or NGF could prevent the severe degenerative loss of serotonergic axons normally caused by the selective 5-HT neurotoxin p-chloroamphetamine (PCA).
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.
- J. Winner, J. Carhart, C. Altar, Josiah D. Allen, B. DeChairo
- Psychology, MedicineDiscover medicine
- 1 November 2013
Pharmaco-genomic-guided treatment with GeneSight doubles the likelihood of response in all patients with treatment resistant depression and identifies 30% of patients with severe gene-drug interactions who have the greatest improvement in depressive symptoms when switched to genetically suitable medication regimens.